Navigation Links
ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board

ADDISON, Texas, March 13 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the appointment of Jeffrey A. Niezgoda, MD, FACHM, FACEP, FAPWCA as Chairman of the Company's Scientific Advisory Board.

Currently, Dr. Jeffrey Niezgoda is the Medical Director of The Centers for Comprehensive Wound Care and Hyperbaric Oxygen Therapy, St. Luke's Medical Center, Aurora Health Care, in Milwaukee, Wisconsin. He also serves as the President and Chief Operating Officer of Hyperbaric & Wound Care Associates, a medical specialty group serving Southeastern Wisconsin and Northern Illinois, and as the President of the American College of Hyperbaric Medicine. Dr. Niezgoda is a nationally recognized wound care expert and has served as faculty at both national as well as international conferences. He has participated on multiple Expert Consensus Panels and has appeared before Medicare and Medicaid Services as a wound care consultant.

Renaat Van den Hooff, President & CEO of ULURU Inc. commented, "We are delighted that Dr. Niezgoda has accepted this important role with the Company. His extensive experience with Altrazeal(TM) has been invaluable and as Chairman of the Scientific Advisory Board, Dr. Niezgoda will help us to accelerate our clinical development and Altrazeal(TM) product development program."

Altrazeal(TM), a transforming powder dressing, is suitable for exuding wounds such as burns, abrasions, trauma, skin graft donor sites, surgical wounds, along with chronic, slow-healing wounds, such as diabetic foot ulcers and venous ulcers. Altrazeal(TM) is an innovative breakthrough, designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment, reducing pain, enhancing patient comfort, ease of application and removal and typically not requiring a secondary dressing.

Dr. Jeffrey A. Niezgoda stated, "I continue to be impressed with the positive clinical results achieved using Altrazeal(TM). This product offers the potential to significantly change the way healthcare providers approach the treatment of wounds and I am pleased to have the opportunity to contribute to accomplish that vision."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, and suitability of Altrazeal(TM), and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 and quarterly report on Form 10-Q for the quarter ended September 30, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. ULURU Inc. Reports Third Quarter 2007 Results
5. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
6. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
9. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
10. ULURU Inc. Reports First Quarter 2008 Financial Results
11. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology: